Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Within 15 business days prior to randomization:
CD4 cell count greater than or equal to 100 cells/mm3.
HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay.
You may not be if
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Bilateral peripheral neuropathy.
Intractable diarrhea.
Proven or suspected acute hepatitis within 30 days prior to study entry.
Concurrent Medication:
Excluded:
\- Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Concurrent Treatment:
Excluded:
Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Patients with the following prior conditions are excluded:
History of acute or chronic pancreatitis.
Prior Medication:
Excluded:
Therapy for any previous disease that may interfere with patient ability to participate in this study.
Excluded within 14 days prior to randomization:
Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy.
Excluded within 3 months of the start of this study or expected need at time of enrollment:
Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential.
Inability to tolerate oral medication.
Prior Treatment:
Excluded:
Therapy for any previous disease that may interfere with patient ability to participate in this study.
Risk Behavior:
Excluded:
Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.
